Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04025554
Other study ID # 190124
Secondary ID 19-N-0124
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date October 25, 2019
Est. completion date October 24, 2023

Study information

Verified date October 25, 2023
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: Multiple sclerosis (MS) is a disease of the central nervous system (CNS). People who have MS may have lesions that form on parts of the CNS, such as the brain. Some of these lesions may be inflamed for a long time. This causes MS to progress. There is no treatment for these lesions. Researchers believe that a drug that decreases inflammation can help. Objective: To see if a drug called anakinra can help clear inflammation in MS brain lesions. Eligibility: People 18 and older with MS and at least one white matter lesion. Design: Participants will be screened with one or more Neuroimmunology Clinic protocols. Participants will have a medical history and physical exam. They will have blood and urine tests. They will have a lumbar puncture. For this, a needle is inserted between the bones in the back, and cerebrospinal fluid is removed. They will also have an MRI of the brain. The MRI scanner is a cylinder surrounded by a strong magnetic field. Participants will lie on a table that slides in and out of the scanner. Participants will repeat the above procedures throughout the study. Participants will get their first dose of anakinra at the clinic. They will administer the rest of the doses themselves, by injection under the skin. Participants will track their daily dosage electronically or in a written drug diary. Participants will have 4 visits while taking the drug. At each visit, sharps boxes and empty vials will be collected. Participants will have 2 follow-up visits after completing treatment. The study will last 28 weeks.


Description:

Objective: The overall goal of this study is to determine the safety, tolerability, and radiological efficacy of up to 12 weeks of subcutaneous injection of anakinra in people with multiple sclerosis and evidence, by magnetic resonance imaging (MRI), of chronic active (also known as smoldering ) lesions in the white matter. Study population: 5 people with progressive or stable MS, at least one paramagnetic rim lesion on 7-tesla MRI, and no new white matter lesion formation for at least 3 months or clinical relapse for at least 12 months, will complete the study. Design: In this open label, dose escalation study, participants will receive up to 12 weeks of subcutaneous anakinra with initial dose of 100 mg daily up to a target dose of 300 mg daily. Study visits will occur every 4 weeks while on treatment, with 2 follow-up visits at 4 and 12 weeks after treatment discontinuation. Outcome measures: The primary outcome measure is disappearance of one or more paramagnetic rims from white matter lesions identified at baseline. Secondary outcomes include safety and tolerability, clinical and radiological outcomes. Exploratory serological and CSF measures will also be obtained to investigate mechanism of action of anakinra and for biomarker development.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date October 24, 2023
Est. primary completion date October 24, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility - INCLUSION CRITERIA: - Age greater than or equal to 18 - Ability to give informed consent - If fertile, agreement to use an effective method of birth control during the study and for up to 3 months after the last dose of the study drug - Agreement not to participate in any other interventional study while participating in this protocol - Diagnosis of MS, either stable or clinically progressive - Prior 7-tesla MRI scan, with high image quality in the judgment of the study neuroradiologist, demonstrating at least one white matter lesion with a paramagnetic rim (41) EXCLUSION CRITERIA: - Pregnancy or current breastfeeding - Use of another investigational agent within 1 month of screening - Active infection and or neutropenia (ANC < 1000 cells/microliter) - History of lymphoma - Known hypersensitivity to administration of anakinra - Previous treatment with anakinra and/or TNF-receptor inhibitor - History of asthma - QuantiFERON-TB gold positive - Prior treatment with anti-CD20 agent (ocrelizumab, rituximab) - Prior treatment with anti-CD52 agent (alemtuzumab) - History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial or interfere with participation for the full duration of the trial; or not in the best interest of the subject to participate, in the opinion of the treating investigator - Renal dysfunction, as defined by Clinical Center guidelines for administration of gadolinium - Liver dysfunction, as indicated by baseline aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 1.5 times the upper limit of normal - Clinical relapse in the 12 months prior to dosing - New lesion formation (by comparison of screening MRI to a previous MRI of sufficient quality) in the 3 months prior to dosing - One or more gadolinium-enhancing lesions on the screening scan - Change in disease-modifying therapy in the 6 months prior to dosing - Medical contraindication for 7-tesla MRI (including, but not limited to, any non-organic implant or other device such as a cardiac pacemaker or infusion pump or other metallic implants, objects, or body piercings, that are not MRI-compatible or cannot be removed) - Psychological contraindication for 7-tesla MRI (e.g., claustrophobia) - Contraindication to gadolinium administration. - Active neoplastic disease or any medical condition, other than MS, that requires concurrent immunosuppression or immunomodulation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Anakinra
100 mg daily weeks 1-4, 200 mg daily weeks 5-8, 300 mg daily weeks 9-12.

Locations

Country Name City State
United States National Institutes of Health Clinical Center Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disappearance of one or all paramagnetic phase rims Assessment of paramagnetic phase rims by scans. At baseline and every 4 weeks
Secondary Symbol digit modalities test (SDMT) Clinical assessment Every 4 weeks for the duarion of study
Secondary Safety and tolerability Monitoring of AEs 28 weeks
Secondary Proportion of paramagnetic rim lesions in which the rim has diminished or disappeared at any time point MRI scan Every 4 weeks for the duration of the study
Secondary Expanded Disability Status Scale (EDSS) Clinical assessment Every 4 weeks for the duarion of study
Secondary Changes in T1 relaxation time within paramagnetic rim lesions at all time points, relative to non-rim lesions MRI scan Every 4 weeks for the duration of the study
Secondary Changes in size of paramagnetic rim lesions at all time points, relative to non-rim lesions MRI scan Every 4 weeks for the duration of the study
Secondary 9-hole peg test (9HPT) Clinical assessment Every 4 weeks for the duarion of study
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis